RB1 and retinoblastoma: While ARL5B was prioritized due to its consistent downregulation in Y79 and Weri-Rb1 cells and its functional association with retinoblastoma cell migration—supported by preliminary overexpression experiments—the remaining candidate proteins require systematic validation and will be the focus of future studies.